Low Complication Rates With Totally Implantable Access Port Use in Epoprostenol Treatment of Pulmonary Hypertension

Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System

“…The number of patient-days contributed by each patient toward the primary end point was obtained from the last date of known followup minus the date of implantation. Sample size calculations were performed based on the OPC determined from complication rates in previous studies, [8][9][10][11][12][13][14] and it was estimated that 22,000 days of followup among 60 patients undergoing implantation would be required to ensure 90% power. A one-sample exact test for the Poisson rate was used to obtain the 97.5% one-sided upper confidence bound of the catheter-related complications.…”

Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension

“…In fact, the intravenous administration of epoprostenol (PGI 2 ) is currently the most effective approach for the treatment of PAH, not only because it can ameliorate symptoms of severe PAH, but because it also prolongs life expectancy [16,17]. One major drawback of PGI 2 is that it is very unstable in blood [18,19], meaning that epoprostenol must be intravenously infused on a continuous basis, thereby drastically decreasing the quality of life (QOL) of patients due to problems associated with cosmetic appearance, transportation of an infusion pump and risk of infection [14,20]. For these reasons, stable PGI 2 analogues such as beraprost sodium (BPS) formulated for various routes of administration (oral, subcutaneous and inhalation) have been developed [5,18].…”